Search

The genome-editing technique uncovered several genes previously not known to influence embryonic development.

… Tuesday, July 2, 2019 Summary With the help of the genome-editing tool CRISPR, developmental biologists at the Sloan Kettering Institute have uncovered a set of genes that was previously unknown to influence cell fate decisions. Life is about choices. That’s as true for cells as it is for people. Every

Meet the students who were awarded fellowships based on academic excellence for the 2020–2021 academic year.

… Thursday, September 17, 2020 Every year, the Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences awards fellowships to two third-year students and six second-year students based on academic excellence. Student stipends at GSK are supported by a variety of sources, including philanthropic

The targeted therapy adagrasib received accelerated approved for colorectal cancer caused by a mutation called KRAS-G12C, when used in combination with the drug cetuximab. MSK investigators have led much of the research that resulted in this combined drug approval.

… Friday, June 21, 2024 The US Food and Drug Administration has granted accelerated approval  for the targeted therapy  adagrasib (Krazati ® )  in combination with the drug  cetuximab (Erbitux ® )  for people with advanced  colorectal cancer  caused by a gene mutation called  KRAS -G12C. Adagrasib is the

La terapia dirigida adagrasib recibió una aprobación acelerada para el cáncer colorrectal causado por una mutación llamada KRAS-G12C, cuando se usa en combinación con el fármaco cetuximab. Los investigadores de MSK han liderado gran parte de la investigación que llevó a la aprobación de esta combinación de fármacos.

… Friday, June 21, 2024 La Administración de Alimentos y Medicamentos de los Estados Unidos ha otorgado la aprobación acelerada  para la terapia dirigida  adagrasib (Krazati ® )  en combinación con el fármaco  cetuximab (Erbitux ® )  para personas con  cáncer colorrectal  avanzado causado por una mutación

Open to patients in January 2020, the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center provides nearly every aspect of cancer care under one roof.

… Wednesday, April 1, 2020 By Jim Stallard The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center began welcoming patients for treatment on January 20, 2020. “This remarkable building creates the space, in every sense of the word, for our breakthrough research and therapies

A new treatment is approved for an especially aggressive kind of colorectal cancer.

… Wednesday, April 29, 2020 Summary People with colorectal cancer whose tumors carry a mutation called BRAF V600E have not done well under standard therapies after earlier treatments did not work. A new approach combining two targeted drugs has just been approved by the FDA after positive results in a

Learn how a new cancer engineering PhD program is attracting leading scientists to come to MSK.

… Friday, September 13, 2024 A visionary new approach to solving problems in cancer science is now fully underway at Memorial Sloan Kettering Cancer Center (MSK), as the inaugural class begins  the Pat and Ian Cook Doctoral Program in Cancer Engineering . Leading researchers — drawn to MSK by the opportunity

Following an approval from the FDA in May 2020, the New England Journal of Medicine has published data from the phase I/II LIBRETTO-001 clinical trial of selpercatinib in advanced RET (REarranged during Transfection)-driven lung and thyroid cancers. MSK’s Alexander Drilon, MD, the recently appointed Chief of the Early Drug Development Service, serves as the lead investigator for multi-site clinical trial.

… Wednesday, August 26, 2020 Results Mark Significant Advances in Targeted Treatment for RET-Driven Cancers, Advancing the Field of Precision Medicine Following an approval from the U.S. Food and Drug Administration (FDA) in May 2020, the New England Journal of Medicine has published data from the phase

Two intraperitoneal chemotherapy approaches are being compared for effectiveness and toxicity in Memorial Sloan Kettering Cancer Center’s phase II clinical trial, which continues to enroll cytoreductive cancer surgery patients with isolated peritoneal metastasis.

… Thursday, May 19, 2016 After surgical cytoreduction Figure 1. After surgical cytoreduction, percutaneous inflow and outflow catheters and IP temperature probes are placed in the peritoneal cavity. The catheters are connected to the perfusion system, and normal saline is heated to 41-43°C and circulated

Whether you’ve been diagnosed with a rare cancer or one that’s more common, MSK doctors can provide a second opinion.

… Thursday, December 18, 2025 Learning that you have cancer can be an overwhelming experience. As you begin researching what steps to take after receiving a  cancer diagnosis , you’ll probably hear a lot about getting a second opinion. Memorial Sloan Kettering Cancer Center (MSK) provides second opinions